Projects per year
Personal profile
Chinese Name
李芳菲
Biography
Dr. Li Fangfei graduated from Ocean University of China with a bachelor's degree in Chemistry in 2007. Following two years of master education in Ocean University, she started her PhD study in Australia under China Scholarship Council (CSC) scholarship in 2009. Dr. Li obtained her PhD degree in Chemistry from University of New South Wales in Australia in 2013. After postdoctoral training at Institute of Microbiology, Chinese Academy of Science in Beijing, she joined school of Chinese Medicine at Hong Kong Baptist University as a postdoctoral fellow in 2015, and then served as a research assistant professor since 2016. In 2021, Dr. Li was appointed as a tenure-track assistant professor.
簡歷
李芳菲教授2007年本科畢業於中國海洋大學化學系，同年保送本校碩士研究生。2009年獲得國家留學基金委（CSC）資助赴澳大利亞新南威爾斯大學攻讀博士學位，2013年取得化學博士學位。回國後在中國科學院北京微生物所進行博士後研究。2015年加入香港浸會大學中醫藥學院進行博士後研究，2016年任職研究助理教授，2021年晉升為助理教授。
李教授的研究致力於腫瘤微環境細胞互作機製及基於新型藥物靶點的創新藥物研發，主要包括以下三個方向：1）胰腺導管癌腫瘤神經侵襲中的腫瘤-神經交互機製；2）腫瘤微環境中炎癥誘導的動態變化；3）來源中藥小分子的新型抗腫瘤藥物研發。她的研究成果主要發表於Nature Communications, Biomaterials, Chemical Science 等國際高水平期刊。
Research Interests
novel anti-cancer therapies and targeted drug delivery.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, UNSW Sydney
Award Date: 31 Dec 2013
Fingerprint
Dive into the research topics where Fangfei LI is active. Topic labels come from the works of this scholar.
- 1 Similar Scholars
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Developing an online self-learning platform of Licensed Pharmacists of Traditional Chinese Medicine Qualification Examination for undergraduates of Pharmacy in Chinese Medicine
LI, F. (PI), XU, J. (CoI), ZHANG, H. (CoI), CHEN, H. (CoI), LI, C. (CoI) & SU, D. D. M. (CoI)
1/01/25 → 30/08/26
Project: Teaching project
-
Equipment Matching Fund - High-performance Slide Scanner
LIU, J. (PI), LI, F. (CoI), YU, Y. (CoI), XU, J. (CoI), FU, X. (CoI), WONG, H. L. X. (CoI), KWAN, H. Y. (CoI) & CHONG, W. P. (CoI)
26/03/24 → 25/03/26
Project: Research project
-
-
Osteosarcoma-specific delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in a patient-derived xenograft model
LI, F. (PI)
1/01/19 → 31/12/22
Project: Research project
-
Abstract A021: Cancer-associated fibroblast-derived CXCL12 as a potential therapeutic target for pancreatic ductal adenocarcinoma immunotherapy
Yang, L., Lu, A. & Li, F., 1 Mar 2025, In: Cancer Research. 85, 5, Supplement, 1 p., A021.Research output: Contribution to journal › Conference article › peer-review
-
Abstract B097: Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma patients defined by a core inflammatory gene network exhibited inflammatory characteristics with high CCN2 expression
Qiao, S., Yang, L., Zhang, G., Lu, A. & Li, F., 1 Feb 2025, In: Cancer Immunology Research. 13, 2, Supplement, B097.Research output: Contribution to journal › Conference article › peer-review
-
Alpha-1 Antitrypsin as a Regulatory Protease Inhibitor Modulating Inflammation and Shaping the Tumor Microenvironment in Cancer
Xiang, S., Yang, L., He, Y., Ding, F., Qiao, S., Su, Z., Chen, Z., Lu, A. & Li, F., 2 Jan 2025, In: Cells. 14, 2, 17 p., 88.Research output: Contribution to journal › Journal article › peer-review
Open Access -
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Chen, Z., Liu, Y., Lyu, M., Chan, C. H., Sun, M., Yang, X., Qiao, S., Chen, Z., Yu, S., Ren, M., Lu, A., Zhang, G., Li, F. & Yu, Y., 1 Feb 2025, In: Cell and Bioscience. 15, 1, 16 p., 13.Research output: Contribution to journal › Journal article › peer-review
Open Access3 Citations (Scopus) -
DeepAptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model
Yang, X., Chan, C. H., Yao, S., Chu, H. Y., Lyu, M., Chen, Z., Xiao, H., Ma, Y., Yu, S., Li, F., Liu, J., Wang, L., Zhang, Z., Zhang, B. T., Zhang, L., Lu, A., Wang, Y., Zhang, G. & Yu, Y., 11 Mar 2025, In: Molecular Therapy Nucleic Acids. 36, 1, 15 p., 102436.Research output: Contribution to journal › Journal article › peer-review
Open Access4 Citations (Scopus)
Prizes
-
The 8th Hong Kong University Student Innovation and Entrepreneurship Competition
LI, F. (Recipient), 2022
Prize: Award
File
Activities
-
Frontiers in Oncology (Journal)
LI, F. (Associate editor)
2024 → …Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
External Reviewer of University of Macau Multi-year Research Grant ( General Research Grant )
LI, F. (Advisor)
16 Apr 2024 → 20 Apr 2024Activity: Consultancy
-
Heliyon (Journal)
LI, F. (Reviewer)
16 Apr 2024Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
Experimental Cell Research (Journal)
LI, F. (Reviewer)
18 Jun 2024Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)
-
Frontiers in Immunology (Journal)
LI, F. (Associate editor)
2024 → …Activity: Publication peer-review/editorial work › Editor/reviewer for publications (incl. CDCF T61 Journal Editor)